menu
    • menu
    [{"orgOrder":0,"company":"Inipharm","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery","graph3":"Inipharm","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inipharm \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"Inipharm \/ Undisclosed"},{"orgOrder":0,"company":"Inipharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"INI-822","moa":"HSD17B13","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Inipharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inipharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inipharm \/ Inapplicable"},{"orgOrder":0,"company":"Inipharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"INI-822","moa":"HSD17B13","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Inipharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inipharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inipharm \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Inipharm

    Menu

    Inipharm

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Inipharm

                            U.S.A arrow
                            CST
                            Not Confirmed

                            Inipharm

                            U.S.A arrow
                            CST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INI-822

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Inipharm Initiates Dosing in Phase 1 Study of its Small Molecule Inhibitor of HSD17B13

                            Details : INI-822 is a small molecule oral inhibitor which works by targeting HSD17B13, it is being investigated for the treatment of non-alcoholic steatohepatitis.

                            Product Name : INI-822

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 30, 2023

                            Lead Product(s) : INI-822

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Inipharm

                            U.S.A arrow
                            CST
                            Not Confirmed

                            Inipharm

                            U.S.A arrow
                            CST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INI-822

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Inipharm to Present Data on Anti-Fibrotic Effects of Its Development Candidate Targeting HSD17B13 at AASLD’s...

                            Details : INI-822 a small molecule inhibitor of HSD17B13, data showed favorable drug properties and in vivo changes in lipid metabolism consistent with those observed with protective forms of HSD17B13.

                            Product Name : INI-822

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 25, 2022

                            Lead Product(s) : INI-822

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Inipharm

                            U.S.A arrow
                            CST
                            Not Confirmed

                            Inipharm

                            U.S.A arrow
                            CST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Discovery

                            Sponsor : Undisclosed

                            Deal Size : $35.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Inipharm Raises $35 Million in Series A to Focus on Highly Validated Genetic Target HSD17B13

                            Details : Inipharm will use the Series A funding to push the lead program — which targets the HSD17B13 gene —through IND filing and into the clinic.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            November 11, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Discovery

                            Sponsor : Undisclosed

                            Deal Size : $35.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth